" siRNA in cell cultures (i.e. I have been able to reduce message levels, but usually only to about 50-70% of the pre-treatment levels)... "
This is not uncommon and we sometimes see it in our lab as well. I am also concerned about how the FDA will handle the issue of "off-target" effects of siRNA, which also appear to be fairly common, difficult to predict, and usually hidden (ie genome-wide expression profiling is needed to rule it out).